|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNF-mediated autocrine growth inhibition may contribute to the maintenance of the stable, chronic phase of this disease and similar mechanisms may operate in other malignancies to limit tumor proliferation.
|
2584719 |
1989 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After T-cell-depleted bone marrow transplantation (TD-BMT), these cells have an activated pattern of target cell killing; they also secrete lymphokines including gamma-interferon (gamma-IFN), interleukin-2 (IL-2), and tumor necrosis factor (TNF) and may have a significant role as a primary defense against viral reactivation and in the elimination of residual host malignancy.
|
2495037 |
1989 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor (TNF) produced by macrophages is thought to contribute to the host defense against development of cancer.
|
2662193 |
1989 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Northern blotting analysis showed the presence of mRNA for tumor necrosis factor (TNF) in 15 of 28 cancer samples and 6 of 26 matched normal areas.
|
2114216 |
1990 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The expression of cytokine genes for tumor necrosis factor alpha (TNF alpha), lymphotoxin and transforming growth factor beta (TGF beta), all of which are known to suppress normal hematopoiesis, was investigated in 32 patients with lymphoid malignancies using Northern blot analysis.
|
2066357 |
1991 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was subsequently demonstrated that, in addition to its oncolytic potential, TNF exerts a wide variety of activities on the host defensive system against malignancies.
|
1579736 |
1992 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To define if alterations of tumor necrosis factor alpha (TNF alpha), interleukin 1 alpha (IL-1 alpha), IL-1 beta and IL-6 gene expression are present in this malignancy, samples from 19 tumors as well as samples from seven paired normal renal tissue were examined using Northern blot and immunohistochemical analysis.
|
8231032 |
1993 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNF antagonists may have therapeutic potential in this malignancy.
|
8387543 |
1993 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rather, the presence of LT, TNF and IL-6 transcripts appeared to characterize Hodgkin and Reed-Sternberg cells in general, supporting concepts which suggest that HD represents a malignancy of cytokine secreting activated cells, and that many of the features distinguishing HD from other malignant lymphomas may ultimately be due to expression of cytokines.
|
8217820 |
1993 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans.
|
8473752 |
1993 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene therapy for cancer is being tested in clinical trials using tumor-infiltrating lymphocytes (TIL) or tumor cells modified by the insertion of genes coding for interleukin 2 or tumor necrosis factor alpha.
|
8101762 |
1993 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together these findings suggest that pentoxifylline can down-regulate TNF expression and improve the sense of well-being in cancer patients.
|
7678547 |
1993 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It appears that TNF is produced mainly in PBMC but not in the cancer regions or the regional lymph nodes of gastric cancer patients.
|
7961104 |
1994 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The most common type of approved clinical trial for cancer gene therapy involves the ex vivo gene transfer of cytokine genes (e.g., tumor necrosis factor, interleukin-2, granulocyte-macrophage colony-stimulating factor) into tumor cells.
|
8149602 |
1994 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene transfer of TNF receptor for treatment of cancer by TNF.
|
8060337 |
1994 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In HNSCC, enhanced expression of TNF receptors on the cancer cells occurs and is likely to contribute to the regulation of TNF and its activation of tumor cells within the tumor microenvironment; targeting these receptors in cancer cells may provide a new approach to controlling tumor growth and metastasis.
|
7485723 |
1995 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicated that F4614 has several advantages as a systemic therapeutic drug in the treatment of cancer.
|
8528939 |
1995 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The potential role of the simultaneous use of DMSO-related molecules, and TNF and/or IFN in leukemic cancer chemotherapy is discussed.
|
8551796 |
1995 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This molecule binds to LeY antigen on cancer cells with the same affinity as B1(scFv) and B1(scFv) immunotoxins but with significantly lower affinity to the TNF receptor compared to the TNF trimer.
|
9816329 |
1996 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The progress in the field of TNF is focussed on gene organization and transcription, gene polymorphism, biochemistry of TNF, TNF receptors and the biological role of TNF in autoimmune diseases, infectious diseases, transplantation, cancer and TNF functions on endothelial cells.
|
8917114 |
1996 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, overall results demonstrate that oligonucleotides directed to the specific regions of TNF can be designed, which may have a potential in cancer therapy.
|
8912851 |
1996 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors.
|
9338474 |
1997 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CD137, a member of the tumor necrosis factor receptor family, is located on chromosome 1p36, in a cluster of related genes, and colocalizes with several malignancies.
|
9207223 |
1997 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that genetic polymorphism leading to increased TNF production influences the outcome of NHL and suggest a pathophysiological role for the genetic control of the immune response in lymphoid malignancies.
|
9572991 |
1998 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this clinical study was to compare levels of CF in HIV-1-positive patients with asymptomatic disease, opportunistic infections, and malignancies with those in HIV-1-negative control groups and to correlate CF activity with CD4+ T cell numbers, the cytokines (TNF-alpha, interleukin-2 [IL-2], IL-6), and the inflammatory markers (C-reactive protein [CRP], neopterin, granulocyte elastase).
|
9642683 |
1998 |